Implications from the SIV model in understanding HIV neutralization

Future HIV Therapy

Volumn 2, Issue 1, 2008, Pages 47-58

  Lauren, Anna ^a   Fenyö, Eva Maria ^b  

^a NOVO NORDISK A S   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Autologous neutralization; CD4 independence; Coreceptor use; Evolution to neutralization; Heterologous neutralization; HIV 1; HIV 2; Pathogenesis; Resistance; SIV

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIVIRAL THERAPY; CROSS REACTION; EPIDEMIC; EXPERIMENTAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; LONG TERM CARE; MACACA; MORTALITY; NONHUMAN; PATHOGENESIS; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

EID: 40349084140     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.1.47     Document Type: Review

References (74)

1. Haigwood NL: Predictive value of primate models for AIDS. AIDS Rev. 6, 187-198 (2004).
2. Johnson WE, Lifson JD, Lang SM, Johnson RP, Desrosiers RC: Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J. Virol. 77, 375-381 (2003).
3. Schmitz JE, Kuroda MJ, Santra S et al.: Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77, 2165-2173 (2003).
4. Lauren A, Thorstensson R, Fenyo EM: Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. J. Gen. Virol. 87, 595-606 (2006).
5. Putkonen P, Thorstensson R, Ghavamzadeh L et al.: Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature 352, 436-438 (1991).
6. Mascola JR, Lewis MG, Stiegler G et al.: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
7. Baba TW, Liska V, Hofmann-Lehmann R et al.: Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000).
8. Nishimura Y, Igarashi T, Haigwood N et al.: Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76, 2123-2130 (2002).
9. Veazey RS, Shattock RJ, Pope M et al.: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003).
10. Zhang YJ, Fracasso C, Fiore JR et al.: Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J. Infect. Dis. 176, 1180-1187 (1997).
11. Pantaleo G, Menzo S, Vaccarezza M et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216 (1995).
12. Pilgrim AK, Pantaleo G, Cohen OJ et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176, 924-932 (1997).
13. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332, 201-208 (1995).
14. Montefiori DC, Pantaleo G, Fink LM et al.: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173, 60-67 (1996).
15. Albert J, Abrahamsson B, Nagy K et al.: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4, 107-112 (1990).
16. Wei X, Decker JM, Wang S et al.: Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
17. Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection, Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
18. Arendrup M, Nielsen G,,Hansen JE, Pedersen C, Mathiesen L, Nielsen JO: Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5, 303-307 (1992).
19. Zhang YJ, Ohman P, Putkonen P et al.: Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis. Virology 197, 609-615 (1993).
20. Ljunggren K, Bottiger B, Biberfeld G, Karlson A, Fenyo EM. Jondal M: Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J. Immunol. 139, 2263-2267 (1987).
21. Ljunggren K, Karlson A, Fenyo EM, Jondal M: Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection, Clin. Exp. Immunol. 75, 184-189 (1989).
22. Banks ND, Kinsey N, Clements J, Hildreth JE: Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18, 1197-1205 (2002).
23. Gomez-Roman VR, Patterson LJ, Venzon D et al.: Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174, 2185-2189 (2005).
24. Florese RH, KK Van Rompay, Aldrich K et al.: Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIV mac251 challenge. J. Immunol. 177, 4028-4036 (2006).
25. Barr TA, Brown S. Ryan G, Zhao J. Gray D: TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur J. Immunol. 37, 3040-3053 (2007).
26. Wyss-Coray T, Gallati. H, Pracht I et al.: Antigen-presenting human T cells and antigen-presenting B cells induce a similar cytokine profile in specific T cell clones. Eur. J. Immunol. 23, 3350-3357 (1993).
27. Rybarczyk BJ, Montefiori D, Johnson PR, West A, Johnston RE, Swanstrom R: Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J. Virol. 78, 3561-3571 (2004).
28. Jiang JD, Bekesi GJ: Antibody responses to HIV-1 antigens are higher in HIV-1(+) intravenous drug users than in HIV-1(+) homosexuals. Biomed. Pharmacother. 55, 313-315 (2001).
29. Burns DP, Collignon C, Desrosiers RC: Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol. 67. 4104-4113 (1993).
30. Chackerian B, Rudensey LM, Overbaugh J: Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies: J Virol. 71, 7719-7727 (1997).
31. Mori K, Sugimoto C, Ohgimoto S et al.: Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model. J. Virol. 79. 10386-10396 (2005).
32. Johnson PR, Hamm TE, Goldstein S, Kitov S,Hirsch VM: The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. Virology 185, 217-228 (1991).
33. Javaherian K, Langlois AJ, Schmidt S et al.: The principal neutralization determinant of simian Immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 89, 1418-1422 (1992).
34. Kent KA, Rud E, Corcoran T et al.: Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res. Hum. Retroviruses 8, 1147-1151 (1992).
35. Overbaugh J, Rudensey LM, Papenhausen MD, Benveniste RE. Morton WR: Variation in simian. immunodeficiency virus env is confined to V1 and V4 during progression to simian. AIDS. J. Virol. 65, 7025-7031 (1991).
36. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC: Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J. Virol. 75, 3903-3915 (2001).
37. Palker TJ, Muir AJ, Spragion DE, Staats HF, Langlois A,Montefiori DC: The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology 224, 415-426 (1996).
38. Barnett SW, Lu S, Srivastava I et al.: The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75, 5526-5540 (2001).
39. Wyatt R, Sullivan N, Thali M et al.: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67, 4557-4565 (1993).
40. Spear GT, Takefman DM, Sharpe S, Ghassemi M, Zolla-Pazner S: Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204, 609-615 (1994).
41. Vogel T, Kurth R, Norley S: The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. J. Immunol. 153, 1895-1904 (1994).
42. Rusche JR, Javaherian K, McDanal C et al.: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl Acad. Sci. USA 85, 3198-3202 (1988).
43. Javaherian K, Langlois AJ, McDanal C et al.: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl Acad. Sci. USA 86, 6768-6772 (1989).
44. Beddows S, Schulke N, Kirschner M et al.: Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79, 8812-8827 (2005).
45. Bjorling E, Scarlatti G, von Gegerfelt A et al.: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193, 528-530 (1993).
46. Shi Y, Brandin E, Vincic E et al.: Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization; envelope sequence and glycosylation. J. Gen. Virol. 86, 3385-3396 (2005).
47. Zhang YJ, Putkonen P, Albert J, Ohman P, Biberfeld G, Fenyo EM: Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. Virology 200, 583-589 (1994).
48. Dhillon AK, Donners H, Pantophlet R et al.: Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81, 16548-6562 (2007).
49. Kolchinsky P, Kiprilov E, Sodroski J: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75, 2041-2050 (2001).
50. Zhang PF, Bouma P, Park EJ et al.: A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76, 644-655 (2002).
51. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A: CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 17, 291-300 (2003).
52. Edwards TG, Hoffman TL, Baribaud F et al.: Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J. Virol. 75, 5230-5239 (2001).
53. Puffer BA, Pohlmann S, Edinger AL et al.: CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J. Virol. 76, 2595-2605 (2002).
54. Vodros D, Thorstensson R, Doms RW, Fenyo EM, Reeves JD: Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. Virology 316, 17-28 (2003).
55. Lauren A, Vincic E, Hoshino H, Thorstensson R, Fenyo EM: CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates. Retrovirology 4, 50 (2007).
56. Dehghani H, Puffer BA, Doms RW, Hirsch VM: Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5. J. Virol. 77, 6405-6418 (2003).
57. Ryzhova E, Whitbeck JC, Canziani G et al.: Rapid progression to simian AIDS can be accompanied by selection of CD4-independent gp120 variants with impaired ability to bind CD4. J. Virol. 76, 7903-7909 (2002).
58. Reeves JD, Hibbitts S, Simmons G et al.: Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J. Virol. 73, 7795-7804 (1999).
59. Hoxie JA, LaBranche CC, Endres MJ et al.: CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. J. Reprod. Immunol. 41, 197-211 (1998).
60. LaBranche CC, Hoffman TL, Romano J et al.: Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J. Virol. 73, 10310-10319 (1999).
61. Hoffman TL, LaBranche CC, Zhang W et al.: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl Acad. Sci. USA 96, 6359-6364 (1999).
62. Dumonceaux J, Nisole S, Chanel C et al.: Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J. Virol. 72, 512-519 (1998).
63. + lymphocytes. J. Virol. 78, 1243-1255 (2004).
64. + T lymphocytes using CD8 as a receptor. Nat. Med. 7, 65-72 (2001).
65. Clapham PR, McKnight A, Weiss RA: Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J. Virol. 66, 3531-3537 (1992).
66. Endres MJ, Clapham PR, Marsh M et al.: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87, 745-756 (1996).
67. Liu, H-y, Soda Y, Shimizu N et al.: CD4-dependent and CD4-independent utilization of coreceptors by human immunodeficiency viruses type 2 and simian immunodeficiency viruses. Virology 278, 276-288 (2000).
68. Karlsson I, Antonsson L, Shi Y et al.: HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 17, 2561-2569 (2003).
69. Karlsson I, Antonsson L, Shi Y et al.: Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J. Virol. 78, 11807-11815 (2004).
70. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834-841 (2005).
71. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 649-659 (1998).
72. Nordqvist A,Fenyo EM: Plaque-reduction assays for human and simian immunodeficiency virus neutralization. Methods Mol. Biol. 304, 273-285 (2005).
73. Shi Y, Albert J, Francis G, Holmes H, Fenyo EM: A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 18, 957-967 (2002).
74. Mörner A, Björndal Å, Albert J et al.: Primary HIV-2 isolates, like HIV-1, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73, 2343-2349 (1999).